- Zacks•58 minutes ago
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
- Zacks•3 hours ago
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
- Reuters•4 hours ago
FRANKFURT/LONDON, March 29 (Reuters) - French drug maker Sanofi has hired advisers for the sale of its European generic drug business, several sources familiar with matter told Reuters, ahead of an auction process which is expected to start after the European summer. Rothschild, JP Morgan and Morgan Stanley have been asked to organise the long-awaited deal which could be worth more than 2 billion euros ($2.2 billion), the sources said. Bankers have been vying for a mandate for the past 18 months since Sanofi boss Olivier Brandicourt took charge of the French firm and decided to put the business under review.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||45.22 - 45.43|
|52 Week Range||36.81 - 45.95|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.38|
|Dividend & Yield||1.58 (3.48%)|
|1y Target Est||N/A|